In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.

EMBO J. 1987 Dec 20;6(13):4067-71. Unique Identifier : AIDSLINE MED/88166651
Dinter H; Chiu R; Imagawa M; Karin M; Jones KA; Molecular Biology and Virology Laboratory, Salk Institute for; Biological Studies, La Jolla, CA 92037.

Abstract: The transition from persistent to lytic infection by the human immunodeficiency virus, HIV, is marked by a burst of viral replication and gene expression that occurs when infected cells are stimulated by physiological inducers or tumor promoters like 12-O-tetradecanoyl phorbol acetate (TPA). We report here that the HIV enhancer is activated specifically by TPA in several non-lymphoid cell types, and that this transcriptional regulation can be reproduced in a cell-free system. In vitro transcription experiments revealed a 6-fold activation of the HIV promoter in nuclear extracts prepared from TPA-induced HeLa tk- cells, whereas a control (human alpha-globin) promoter was transcribed with equal efficiency in either induced or uninduced cell extracts. A corresponding increase in the activity of a cellular DNA-binding protein that interacts with the HIV enhancer was detected in TPA-treated cells with DNase I footprint experiments. This increase occurred in the absence of de novo protein synthesis, suggesting a post-transcriptional activation mechanism. Analysis of HIV deletion mutants suggests that the enhancer is the target for the TPA effect both in vitro and in vivo. The cell-free system described here should facilitate studies on the mechanism of phorbol ester induction of gene-specific transcription factors.

Keywords: Cell Line Enhancer Elements (Genetics)/*DRUG EFFECTS Gene Expression Regulation/*DRUG EFFECTS Genes, Viral/*DRUG EFFECTS Hela Cells/DRUG EFFECTS Human HIV/DRUG EFFECTS/*GENETICS RNA, Viral/GENETICS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Tetradecanoylphorbol Acetate/*PHARMACOLOGY Transcription, Genetic/DRUG EFFECTS JOURNAL ARTICLE

880730
M8870487

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .